Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2016 · 10-Q
Revenue$1.79M$1.79M−11.0% vs Q3 2015 Net Income-$242.58K-$242.58KN/M vs Q3 2015 EPS Diluted-$0.01-$0.01— vs Q3 2015 Gross Profit$1,062,741+10.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$126,856−47.6% Free Cash Flowderived$61,248— Margins · derivedGross margin59.5%+11.5 pt vs Q3 2015
Operating margin-14.0%−18.3 pt vs Q3 2015
Net margin-13.6%−18.0 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 7, 2016 · 38 d after period end